Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 15/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | GSK3B | P49841 | 9/20 | 0.64 |
| ▸ | PRKACA | P17612 | 6/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718290 | 0.88 | RPS6KB1 (0.78) | RPS6KB1ROCK1GSK3BPRKACARPS6KA5 | |
| SCHEMBL14364625 | 0.81 | RPS6KB1 (1.00) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL4805260 | 0.79 | RPS6KB1 (0.66) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL14364626 | 0.79 | RPS6KB1 (1.00) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL14364630 | 0.79 | RPS6KB1 (1.00) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL1903910 | 0.78 | RPS6KB1 (1.00) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL4718378 | 0.77 | RPS6KB1 (0.62) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL1897408 | 0.75 | RPS6KB1 (1.00) | RPS6KB1ROCK1GSK3BPRKACATSHR | |
| SCHEMBL3068154 | 0.75 | TSHR (0.66) | RPS6KB1ROCK1TSHRKMT2ALMNA | |
| SCHEMBL6407637 | 0.74 | RPS6KB1 (0.81) | RPS6KB1ROCK1GSK3BPRKACATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | RPS6KB1 417/4885ROCK1 133/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.